Pharmacokinetics of Pentoxifylline and Its Main Metabolites in Patients With Different Degrees of Heart Failure Following a Single Dose of a Modified‐Release Formulation
Authors:
- 1 January 2013
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (1) , 51-57
Abstract
Pentoxifylline (PTX) is extensively metabolized in the body, and all its 3 plasma metabolites (M1, M4, M5) are pharmacologically active. The authors evaluated the pharmacokinetics of PTX and its metabolites in 20 patients with chronic heart failure (CHF). Eleven had moderate and 9 severe CHF. The time courses of PTX, M1, M4, and M5 plasma levels were determined after oral administration of a sustained‐release 600‐mg tablet of PTX, and for each compound, AUC, maximal plasma concentration (Cmax), and time to Cmax (Tpeak) were calculated. Compared with patients with moderate CHF, those with severe CHF showed a significant delay in Tpeak of PTX (3.9 vs 1.6 hours) and M5 (5.6 vs 3.6 hours), a 59% significant increase in M5 AUC, and a 56% nonsignificant increase in PTX AUC. In the whole population, the AUCs of PTX, M4, and M5 were inversely correlated with markers of liver function, whereas the AUCs of M4 and M5 were inversely correlated with the creatinine clearance. In view of the kinetic features of slow‐release formulations (flip‐flop phenomenon), the delay in Tpeak of PTX in patients with severe CHF compared with moderate CHF should be ascribed to a reduced elimination rate.Keywords
This publication has 22 references indexed in Scilit:
- Immunological Mechanisms of Pentoxifylline in Chronic Heart FailureEuropean Journal of Heart Failure, 2009
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Therapy of Ischemic Cardiomyopathy With the Immunomodulating Agent PentoxifyllineCirculation, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Stereoselective metabolism of pentoxifylline in vitro and in vivo in humansChirality, 2002
- Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathyThe Lancet, 1998
- Comparison of Pentoxifylline Pharmacokinetics Between Smokers and NonsmokersThe Journal of Clinical Pharmacology, 1992
- Clinical Pharmacokinetics in Heart FailureClinical Pharmacokinetics, 1988
- PentoxifyllineDrugs, 1987
- Kinetic Analysis of Blood Levels and Urinary Excretion in the Absorptive Phase after Single Doses of DrugJournal of Pharmaceutical Sciences, 1964